The Role of Interventional Radiology and Image-Guided Ablation in Primary Liver Cancer

Liver Cancers ◽  
2018 ◽  
pp. 109-122
Author(s):  
Jen-Jou Wong ◽  
Nabil Kibriya
Keyword(s):  
Interventional Radiology ◽  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Image Guided

scholarly journals Natural Killer–Dendritic Cell Interactions in Liver Cancer: Implications for Immunotherapy

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2184
Author(s):  
Valentina Cazzetta ◽  
Sara Franzese ◽  
Claudia Carenza ◽  
Silvia Della Bella ◽  
Joanna Mikulak ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Immune Responses ◽  
Nk Cells ◽  
Natural Killer ◽  
Tumor Cells ◽  
Primary Liver Cancer ◽  
Circulating Antigens ◽  
Direct Cytotoxicity ◽  
Immune Changes

Natural killer (NK) and dendritic cells (DCs) are innate immune cells that play a crucial role in anti-tumor immunity. NK cells kill tumor cells through direct cytotoxicity and cytokine secretion. DCs are needed for the activation of adaptive immune responses against tumor cells. Both NK cells and DCs are subdivided in several subsets endowed with specialized effector functions. Crosstalk between NK cells and DCs leads to the reciprocal control of their activation and polarization of immune responses. In this review, we describe the role of NK cells and DCs in liver cancer, focusing on the mechanisms involved in their reciprocal control and activation. In this context, intrahepatic NK cells and DCs present unique immunological features, due to the constant exposure to non-self-circulating antigens. These interactions might play a fundamental role in the pathology of primary liver cancer, namely hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Additionally, the implications of these immune changes are relevant from the perspective of improving the cancer immunotherapy strategies in HCC and ICC patients.

scholarly journals Oncogenic role of the Notch pathway in primary liver cancer

2016 ◽  
Vol 12 (1) ◽  
pp. 3-10 ◽  
Author(s):  
JIE LU ◽  
YUJING XIA ◽  
KAN CHEN ◽  
YUANYUAN ZHENG ◽  
JIANRONG WANG ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Notch Pathway

THU-473-Role of intracellular lysyl oxidase in progression of primary liver cancer

2019 ◽  
Vol 70 (1) ◽  
pp. e368
Author(s):  
Monika Lewinska ◽  
Deepak Kumar Bhatt ◽  
Letizia Satriano ◽  
Douglas VNP Oliveira ◽  
Friederike Mahn ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Lysyl Oxidase ◽  
Primary Liver Cancer

scholarly journals The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer

2017 ◽  
Vol 24 (3) ◽  
pp. 107327481772924 ◽  
Author(s):  
Ashok Shiani ◽  
Shreya Narayanan ◽  
Luis Pena ◽  
Mark Friedman
Keyword(s):  
Liver Disease ◽  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Diagnosis And Treatment ◽  
Underlying Liver Disease

scholarly journals Role of the Plasma Membrane Transporter of Organic Cations OCT1 and Its Genetic Variants in Modern Liver Pharmacology

2013 ◽  
Vol 2013 ◽  
pp. 1-13 ◽  
Author(s):  
Elisa Lozano ◽  
Elisa Herraez ◽  
Oscar Briz ◽  
Virginia S. Robledo ◽  
Jorge Hernandez-Iglesias ◽  
...  
Keyword(s):  
Plasma Membrane ◽  
Liver Cancer ◽  
Genetic Variants ◽  
Current Knowledge ◽  
Primary Liver Cancer ◽  
Target Cells ◽  
Target Tissue ◽  
Cationic Drugs ◽  
Drug Concentrations

Changes in the uptake of many drugs by the target cells may dramatically affect the pharmacological response. Thus, downregulation ofSLC22A1, which encodes the organic cation transporter type 1 (OCT1), may affect the response of healthy hepatocytes and liver cancer cells to cationic drugs, such as metformin and sorafenib, respectively. Moreover, the overall picture may be modified to a considerable extent by the preexistence or the appearance during the pathogenic process of genetic variants. Some rare OCT1 variants enhance transport activity, whereas other more frequent variants impair protein maturation, plasma membrane targeting or the function of this carrier, hence reducing intracellular active drug concentrations. Here, we review current knowledge of the role of OCT1 in modern liver pharmacology, which includes the use of cationic drugs to treat several diseases, some of them of great clinical relevance such as diabetes and primary liver cancer (cholangiocarcinoma and hepatocellular carcinoma). We conclude that modern pharmacology must consider the individual evaluation of OCT1 expression/function in the healthy liver and in the target tissue, particularly if this is a tumor, in order to predict the lack of response to cationic drugs and to be able to design individualized pharmacological treatments with the highest chances of success.

The changing role of surgery in the treatment of primary liver cancer

1986 ◽  
Vol 2 (2) ◽  
pp. 103-112 ◽  
Author(s):  
Zhao-You Tang ◽  
Ye-Qin Yu ◽  
Xin-Da Zhou
Keyword(s):  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Changing Role

scholarly journals Baruch Blumberg (1925-2011) and the discovery of the Hepatitis B virus

2021 ◽  
pp. 18-21
Author(s):  
Bob Weintraub
Keyword(s):  
Hepatitis B Virus ◽  
Liver Cancer ◽  
Hepatitis B ◽  
Genetic Polymorphisms ◽  
Nobel Prize ◽  
Primary Liver Cancer ◽  
Diagnostic Methods ◽  
Inherited Susceptibility ◽  
B Virus

Baruch Blumberg’s research was designed to gain a better understanding of the role of human genetic polymorphisms in relation to inherited susceptibility to disease. This led to the discovery of the hepatitis B virus, diagnostic methods for viral detection, and a vaccine. The vaccination program has prevented the death of millions from primary liver cancer. It was the first widely used vaccine against cancer. For his work with the hepatitis B virus, Blumberg was honored in 1976 by the award of the Nobel Prize in Medicine or Physiology.

Sign in / Sign up

Export Citation Format

Share Document